ArticleBlood advances2024

Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.

Pier Luigi Zinzani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.